Background {#Sec1}
==========

Cancer is a leading cause of death in North America and Europe \[[@CR1], [@CR2]\], and cancer patients are at high risk for life-threatening complications as a result of infection \[[@CR3]\], toxicity of intensive treatments \[[@CR4]\] or targeted therapies \[[@CR5]\], warranting admission to the intensive care unit (ICU). Despite evidence that ICU mortality rates have declined significantly over the last two decades \[[@CR6], [@CR7]\], and although the number and extent of comorbidities, pre-existing performance status along with organ failure have been demonstrated to be the main prognostic factors in this setting \[[@CR8]--[@CR10]\], intensivists may be reluctant to admit specific cancer patient populations such as neutropenic patients.

Although meaningful survival has been described in neutropenic patients \[[@CR11], [@CR12]\], the prognostic impact of neutropenia remains controversial. Neutropenia remains a common side effect of cancer chemotherapy and, although transient, may lead to immune dysfunction. Clinical consequences of neutropenia are well known and include occurrence of sepsis or acute respiratory failure \[[@CR13]\], worsening of respiratory status during neutropenia recovery \[[@CR14]\] and need for specific management \[[@CR15]\]. In contrast to critically ill cancer patients, neutropenia was found to be an independent risk factor of poor outcome in the general ICU population \[[@CR16]\]. The lack of prognostic impact in critically ill cancer patients may thus reflect an absence of statistical power or the influence of coexistent mechanisms of immune deficiency in these patients. In a previous systematic review performed on aggregated data, neutropenia was associated with an increase in relative risk of death of 10% in critically ill cancer patients \[[@CR17]\]. With regards to the limited number of studies reporting an adjusted impact of neutropenia, however, this preliminary study failed to demonstrate an independent impact of neutropenia on outcome \[[@CR17]\].

The aim of this study was to assess influence of neutropenia on outcome of critically ill cancer patients by a meta-analysis of individual data. Secondary objectives were to assess influence of neutropenia on outcome of critically ill patients in prespecified subgroups (according to underlying tumor, period of admission, need for mechanical ventilation and use of granulocyte colony stimulating factor (G-CSF)).

Methods {#Sec2}
=======

This systematic review and meta-analysis of individual data was performed according to the guidelines on Meta-analysis of Observational Studies in Epidemiology \[[@CR18]\]. This study was registered on the PROSPERO database (CRD42015026347). This study was a preplanned follow-up study of an initial meta-analysis on aggregated data \[[@CR17]\].

Study outcome and definitions {#Sec3}
-----------------------------

The aim of this meta-analysis of individual data was to determine the prognostic impact of neutropenia on outcome of critically ill cancer patients.

Neutropenia was defined as a neutrophil count (or if missing as a white blood cell count) lower than 1 G/L (stage 3 or more according to Common Terminology Criteria for Adverse Events version 4.03) (<https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf>).

Outcome was defined as hospital mortality or day-28 mortality if the former was unavailable (Table [1](#Tab1){ref-type="table"}). Choice of this outcome variable was driven by availability of data precluding use of longer follow-up such as day 90. Although ICU mortality was available for most of the reported studies, this variable is more prone to be influenced by the discharge policy in participating centers and a longer follow-up period was preferred \[[@CR19]\].Table 1Included studies' characteristicsAuthor, yearFollow-up*n*SAPS II equivalentProspective studyNumber of centersSolid tumors (%)Mortality (%)Risk of biasCanet et al., 2013 \[[@CR34]\]Hospital20034 (24--50)Yes1030.07Depuydt et al., 2010 \[[@CR33]\]Hospital13725 (20--30)No12.262.87Bird et al., 2012 \[[@CR27]\]Hospital19921 (17--25)Yes1054.35Hill et al., 2012 \[[@CR28]\]Hospital14762 (48--80)No5073.55Müller et al., 2013 \[[@CR35]\]Hospital3457 (31--97.75)No110044.15Namendys-Silva et al., 2012 \[[@CR30]\]Hospital18440 (31--51)Yes130.458.26Yeo et al., 2012 \[[@CR48]\]Hospital22754 (37--71)No1089.97Oeyen et al., 2013 \[[@CR36]\]Hospital48334 (22--48)Yes182.416.46Ferra et al., 2007 \[[@CR37]\]Hospital10060 (44.25--71)Yes1064.05Soares et al., 2006 \[[@CR20]\]Hospital30956 (45--68)Yes124.664.17Soares et al., 2007 (*Chest*) \[[@CR38]\]Hospital14344 (32.5--57)Yes210058.76Soares et al., 2007 (*Intensive Care Med*) \[[@CR44]\]Hospital12147 (37--62)Yes1056.26Soares et al., 2008 \[[@CR32]\]Hospital109044 (32--56.75)Yes181.851.27Soares et al., 2010 \[[@CR25]\]Hospital71729 (19--42)Yes289330.47Souza-Dantas et al., 2011 \[[@CR45]\]Hospital18862 (48.75--73)No131.975.57Soares et al., 2014 (46)Hospital44944 (33--55)Yes2210038.85Song et al., 2011 \[[@CR26]\]Hospital6241 (25--51)No12169.46Yoo et al., 2013 \[[@CR42]\]Hospital21444 (35--59)No146.349.17Lee et al., 2015 \[[@CR43]\]Hospital52561.5 (51--70)Yes140.256.07Mokart et al., 2007 \[[@CR21]\]28 days5149 (35.5--70.25)Yes121.643.15Mokart et al., 2012 \[[@CR47]\]Hospital11145 (33--55)Yes121.640.56Adda et al., 2008 \[[@CR41]\]Hospital9949 (39.5--57)No1061.66Burghi et al., 2011 \[[@CR40]\]28 days59NANo1072.97Legriel et al., 2010 \[[@CR23]\]Hospital10155 (42--67)No129.744.65Xhaard et al., 2013 \[[@CR29]\]Hospital62NANo1041.95Azoulay et al., 2008 \[[@CR22]\]Hospital148NAYes112.855.46Azoulay et al., 2013 \[[@CR8]\]28 days101129 (23--39)Yes17038.27McGrath et al., 2010 \[[@CR24]\]Hospital18539 (26--47)No137.831.45Wohlfarth et al., 2014 \[[@CR31]\]Hospital5650 (39--60.5)No114.341.15Toffart et al., 2011) \[[@CR39]\]Hospital10344 (33--57)No310031.17*SAPS* Simplified Acute Physiology Score

Search strategy and eligibility assessment {#Sec4}
------------------------------------------

First, public-domain databases including PubMed and the Cochrane database were searched using Exploded Medical Subject Headings and the appropriate corresponding keywords: "NEOPLASM" OR "MALIGNANCY" OR "CANCER" AND "INTENSIVE CARE UNIT" OR "ICU". The research was restricted to publications in English and studies concerning humans from May 2005 to May 2015. Studies published before 2005 not included to limit heterogeneity across studied populations that may have arisen with regard to prognostic change of both critically ill and critically ill cancer patients \[[@CR20], [@CR21]\]. Abstracts were carefully checked and studies focusing on children or patients aged younger than 18 years old, case reports and studies failing to focus on critically ill patients were excluded.

All remaining references were then downloaded for consolidation, elimination of duplicates and further analysis. Four investigators (Marie Bouteloup, Sophie Perinel, DM, MD) independently determined the eligibility of all studies identified in the initial research. Last, studies with explicit redundancies were only included once (for this study, redundancies were assessed by QG and MD).

Each of the included studies obtained approval of a local or a national ethic committee in accordance with local legislation. Patients or their next of kin consented to participate or were informed of the included study and did not oppose participation according to local legislation. With regard to its retrospective design and lack of change of the primary outcome variable, the need for additional ethic committee approval was waived according to French Law.

Patients were not involved in the included studies' design. The primary outcome measure was defined according to its clinical relevance for both patients and carers. Health care providers were involved in patient recruitment. Last, the patients and physicians involved in the analyzed studies are thanked in Acknowledgements.

Data and quality assessment {#Sec5}
---------------------------

Investigators of selected publications were contacted twice and invited to participate in this study. Authors who agreed to participate were asked to send a file containing individual data including: age, gender, year of admission, underlying malignancy (solid tumor vs hematological malignancy), history of allogeneic stem cell transplantation, severity score, need for organ support (invasive mechanical ventilation, vasopressor use, renal replacement therapy), neutropenia during ICU stay, neutropenia duration, use of granulocyte colony stimulating factor (G-CSF), follow-up and outcome.

To enable study comparison, we transformed illness severity scores (Acute Physiology and Chronic Health Evaluation (APACHE) II and APACHE III) into the equivalent Simplified Acute Physiology Score (SAPS) II, using a previously described methodology \[[@CR22]\]. When neither the APACHE II score nor the APACHE III score was available, the available severity score was transformed into the SAPS II according to the estimated odds of dying during the ICU stay.

Risk of bias of included studies was assessed using the "risk bias in cohort study" tool developed by the Cochrane group (<http://methods.cochrane.org/sites/methods.cochrane.org.bias/files/public/uploads/Tool%20to%20Assess%20Risk%20of%20Bias%20in%20Cohort%20Studies.pdf>; accessed February 2, 2017).

Statistical analysis {#Sec6}
--------------------

All quantitative variables were described using medians (quartiles) while qualitative variables were described with their frequencies (percentage). The overall association between mortality and patient characteristics was determined with a one-step meta-analysis approach. Univariate analyses were performed using a logistic regression model with random study effects to obtain odds ratios (ORs) with their two-sided 95% confidence intervals (CIs) as measures of relative risk. Variables identified as being associated with mortality in univariate analyses, with *P* \< 0.20, were included in a multivariate logistic regression model with a random study effect. Chi-square heterogeneity tests were used to test for statistical heterogeneity among studies. The *I*^2^ index (expressing the proportion of variability of the results related to heterogeneity) was reported.

Strata analyses were performed using the statistical plan already described for the following strata: patients with ICU admission after 2007 (median ICU admission period in the studied population), patients with hematological malignancy, patients requiring mechanical ventilation and patients receiving G-CSF.

All effect sizes with *P* \< 0.05 were considered significant. All analyses were carried out with software R, version 3.2.5. The lme4 and Meta package were used to take into account the random effects and to produce forest plots.

Results {#Sec7}
=======

Our initial search yielded 1528 citations, of which 38 were excluded due to duplication and 706 were excluded as irrelevant for the scope of this review. All abstracts of the remaining 784 records were carefully checked and 131 full-text articles focusing on critically ill cancer patients' prognosis were scrutinized for further evaluation. Seventeen studies were excluded, including 10 studies with redundancies, five studies lacking neutropenic, non-neutropenic patients or major data required for the analysis, and two studies including only palliative patients. Among the remaining 114 studies, authors of 30 studies (26.3% of selected studies) agreed to participate in this study, leading to a dataset of 7515 patients, including 1702 neutropenic patients (22.6%) (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR8], [@CR23]--[@CR51]\].Fig. 1Flow chart of study selection

Characteristics of included studies {#Sec8}
-----------------------------------

The included studies were published from 2006 to 2015. Sixteen were prospective cohort studies (53%) and six (20%) were multicentric cohort studies (Table [1](#Tab1){ref-type="table"}). The variable of outcome was hospital mortality in 27 studies and 28-day mortality in three studies. Overall, the number of patients included per study was 166 (IQR 99--266) and ranged from 34 \[[@CR38]\] to 1090 \[[@CR35]\].

Characteristics of the patients {#Sec9}
-------------------------------

Of the 7515 included patients, three were excluded due to missing major variables (neutropenia or mortality) leading to analysis of 7512 patients. Of these patients, 4943 were included in monocenter studies (65.8%) and 5841 (77.8%) in prospective studies (Table [2](#Tab2){ref-type="table"}).

Median age was 60 years (49--69) and median SAPS II was 42 (28--57) (Table [2](#Tab2){ref-type="table"}). Overall, 3366 patients (44.8%) had a solid tumor and 439 patients were allogeneic stem cell transplant recipients (5.8%). Respectively, 3710 patients (49.4%), 3084 patients (41.1%) and 1201 patients (16%) required invasive mechanical ventilation, vasopressors or renal replacement therapy.Table 2Patient characteristicsVariableMissing data, *n* (%)Overall population (*n* = 7515)Neutropenic patients (*n* = 1702)^a^Non-neutropenic patients (*n* = 5810)^a^*P*\
valueAge (years)15 (0.2%)60 (49--69)55 (41--64)61 (51--70)\< 0.001ICU admission year02007 (2004--2010)2008 (2005--2010)2007 (2004--2010)\< 0.001Underlying malignancy Solid tumors0 (0%)3366 (44.8%)232 (13.6%)3131 (53.9%)\< 0.001 Hematological malignancy0 (0%)4149 (55.2%)1470 (86.4%)2679 (46.1%)\< 0.001 Allogeneic HSCT0 (0%)439 (5.8%)186 (10.9%)253 (4.4%)\< 0.001SAPS II503 (6.7%)41 (28--57)51 (34--68)39 (26--54)\< 0.001Organ support at ICU admission Mechanical ventilation1 (0%)3804 (50.6%)964 (56.6%)2839 (48.9%)\< 0.001 Vasopressors0 (0%)3084 (41%)954 (56.1%)2129 (36.6%)\< 0.001 Renal replacement therapy58 (0.8%)1201 (16%)386 (22.7%)815 (14%)\< 0.001Mortality2 (0%)3538 (47.1%)1021 (60%)2517 (43.3%)\< 0.001*HSCT* hematopoietic stem cell transplantation, *SAPS* Simplified Acute Physiology Score, *ICU* intensive care unit^a^Data on neutropenia unavailable in three patients (0.03%)

Outcome {#Sec10}
-------

Unadjusted mortality in the studied population was 47.1% (*n* = 3538), including mortality of 60.2% (*n* = 1025) and 43.2% (*n* = 2504) in neutropenic and non-neutropenic patients, respectively (*P* \< 0.001).

After adjustment for confounders, and taking study effect into account, neutropenia was independently associated with mortality (OR 1.41; 95% CI 1.23--1.62; *P* = 0.03) (Table [3](#Tab3){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}).Table 3Factors independently associated with mortality after adjustment for confounders (mix-linear model taking study effect into account)VariableOdds ratio95% CI*P* valueNeutropenia1.411.23--1.620.03Age \< 50 yearsReference----Age 50--59 years1.110.95--1.280.18Age 60--69 years1.321.13--1.53\< 0.001Age 69+ years1.661.43--1.94\< 0.001Solid tumors (vs HM)0.690.58--0.81\< 0.001Allogeneic HSCT1.911.50--2.43\< 0.001Mechanical ventilation3.012.66--3.41\< 0.001Vasopressors2.071.83--2.35\< 0.001Renal replacement therapy1.501.29--1.75\< 0.001*CI* confidence interval, *HM* hematological malignancy, *HSCT* hematopoietic stem cell transplantationFig. 2Summary of adjusted prognostic impact of neutropenia on mortality in the included studies. CI confidence interval, OR odds ratio, ICM Intensive Care Med, n.c., not counted (no event)

Influence of neutropenia in predefined subgroups {#Sec11}
------------------------------------------------

When analyzed separately, neither admission period, underlying malignancy nor need for mechanical ventilation modified the influence of neutropenia on outcome (Additional file [1](#MOESM1){ref-type="media"}: Tables S1--S3).

In patients admitted after 2007 (median admission period; *n* = 3563, including 880 neutropenic patients), neutropenia was independently associated with an increased mortality (OR 1.40; 95% CI 1.16--1.70; *P* \< 0.001).

In patients with hematological malignancy (*n* = 4149, including 1470 neutropenic patients), neutropenia was independently associated with an increased mortality (OR 1.30; 95% CI 1.11--1.51; *P* \< 0.001).

Among the included patients, data on use of G-CSF was available for 1949 patients (25.9%). Among the 788 patients receiving G-CSF, 587 were neutropenic. After adjustment for confounders (Additional file [1](#MOESM1){ref-type="media"}: Table S4), neutropenia was not independently associated with outcome (OR 1.03; 95% CI 0.70--1.51; *P* = 0.90).

Discussion {#Sec12}
==========

This large dataset resulting from systematic review of individual data confirms neutropenia to be independently associated with mortality in critically ill cancer patients. According to our results, the prognostic impact of neutropenia was unchanged when stratifying for malignancy, period of ICU admission or use of mechanical ventilation. However, in patients treated with G-CSF, neutropenia was no longer associated with mortality, suggesting that the use of G-CSF may influence the prognostic impact of neutropenia in this setting.

Neutropenia remains an accepted side effect of most treatments administered to hematological patients \[[@CR52]\]. Neutropenia is associated with complications that include severe sepsis \[[@CR53]\], acute respiratory failure \[[@CR54]\] and specific conditions such as neutropenic enterocolitis \[[@CR55]\]. Although these side effects are likely to influence the outcome of critically ill patients, results of studies in this field remain controversial. Although neutropenia remains associated with a poor outcome in general ICU populations \[[@CR16]\], several recent studies failed to demonstrate an impact of neutropenia on the outcome of critically ill cancer patients \[[@CR8], [@CR12]\]. The numerous mechanisms of immune deficiency in these patients, along with the prognostic influence of disease severity or need for organ support therapies, might explain these negative findings. A previous systematic review, based on aggregated data, suggested that neutropenia was associated with a 10% increase in overall mortality but the result may have been confounded by studies with negative findings due to lack of statistical power \[[@CR17]\]. In fact, the influence of neutropenia was no longer significant after adjusting for confounders but in a limited study population \[[@CR17]\]. Results of our study confirm that, even after adjustment for confounders, neutropenia is associated with a poor outcome. These data strongly suggest that neutropenia, conversely to the recently published recommendations \[[@CR15]\], should be considered a prognostic factor. Additional studies are needed to confirm our results and to identify room for improvements in the management of this specific population.

In most of the predefined subgroups, namely according to underlying malignancy, use of mechanical ventilation or according to ICU admission period, the impact of neutropenia on outcome was unchanged. However, it must be noted that the impact of neutropenia was no longer associated with outcome in patients treated with G-CSF. Prophylactic use of G-CSF in patients with hematological malignancy or solid tumors has proven efficacy in decreasing the risk or duration of neutropenia, in limiting the risk of infectious disease and in specific settings decreasing both overall mortality and infection-related mortality \[[@CR56], [@CR57]\]. Conversely, use of G-CSF in patients with already overt infections (curative G-CSF) was found to have a limited benefit in neutropenic patients \[[@CR58], [@CR59]\]. Data regarding interest of prophylactic or curative use of G-CSF are limited to studies with high risk of bias and suggest a limited efficacy in this setting \[[@CR60]--[@CR62]\]. In addition, G-CSF remains associated with potential side effects, including risk of worsening respiratory status during neutropenia recovery \[[@CR63]\]. Our study is the first to date to suggest indirectly that G-CSF may limit the prognostic impact of neutropenia in critically ill patients. Although this result is insufficient to modify existing recommendations, additional interventional studies in this setting may be warranted.

This study has several important limitations. Firstly, despite the biological plausibility, this study at best demonstrated a statistical association between neutropenia and mortality. Whether this statistical association may be due to a causal relationship remains to be demonstrated. Secondly, the observed dependent association that might have been affected by allocation bias not taken into account by our analysis. In line with this, available data did not allow adjustment for center or volume effect, assessment of the impact of organizational processes \[[@CR64]\], influence of duration of neutropenia or influence of several management strategies including impact of antifungal prophylaxis. Last, only a quarter of identified studies were ultimately included. However, it must be noted that the large dataset, and the analysis adjusting for study influence and modeling of unrecorded data by using a mixed effect model, should have, at least partly, taken these effects into account. In line with this, several arbitrary choices were made during analysis as regards the study inclusion period or cutoff point to define the ICU admission period. The lack of other reliable cutoff points, however, is to be noted when taking into account these limits. Last, the influence of G-CSF was assessed only indirectly, in a subset of patients in whom the use of G-CSF was recorded, without information regarding the rational for its prescription. Thus, our negative results might reflect either a lack of statistical power or an inclusion bias. Nevertheless, our results are a strong plea for further interventional studies to assess the influence of G-CSF in critically ill patients with neutropenia.

Conclusion {#Sec13}
==========

This systematic review, comprising 7515 patients, suggests a meaningful survival in neutropenic critically ill patients despite an independent association with poor outcome. Neither underlying malignancy, a period of admission nor use of mechanical ventilation significantly modified this result. Interestingly, neutropenia was no longer significantly associated with outcome in patients treated with G-CSF. Thus, our results may suggest a beneficial effect of G-CSF in critically ill cancer patients and serve as a plea for additional studies in this field.

Key messages {#Sec144}
============

This systematic review of individual data suggests a meaningful survival in neutropenic critically ill patients despite an independent association with poor outcome.Neutropenia is no longer significantly associated with outcome in patients treated with G-CSF, suggesting a beneficial effect of this therapy in critically ill cancer patients.The independent association of neutropenia with poor outcome suggest additional research to be required in way to limit excess of mortality in this subgroup of critically-ill patients.Potential beneficial effect of G-CSF in critically-ill neutropenic patients is a plea for additional studies assessing benefits of therapeutic G-CSF in this subgroup of patients.
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===============

 {#Sec14}

Additional file 1:**Table S1.** Factors independently associated with mortality after adjustment for confounders among patients with ICU admission after 2007 (mix-linear model taking study effect into account). **Table S2.** Factors independently associated with mortality after adjustment for confounders among patients with hematological malignancy (mix-linear model taking study effect into account). **Table S3.** Factors independently associated with mortality after adjustment for confounders among patients requiring mechanical ventilation (mix-linear model taking study effect into account). **Table S4.** Factors independently associated with mortality after adjustment for confounders among patients receiving G-CSF (mix-linear model taking study effect into account) (DOC 58 kb)

APACHE

:   Acute Physiology and Chronic Health Evaluation

G-CSF

:   Granulocyte colony stimulating factor

HSCT

:   Hematopoietic stem cell transplant

ICU

:   Intensive care unit

SAPS

:   Simplified Acute Physiology Score
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